Usted buscó: mast cell (Inglés - Maltés)

mast cell tumours are cancerous proliferations of mast cells.
it-tumuri tal-mast cell huma proliferazzjonijiet kanċerużi tal-mast cells.

masivet is a prescription medicine used to treat dog mast cell tumours.
masivet huwa mediċina bir-riċetta li tintuża għat-trattament ta’ tumuri tal-mast cell fil-klieb.

in certain circumstances, mast cell tumours can be life threatening for your dog.
f’ċerti ċirkustanzi, it-tumuri tal-mast cell jistgħu jkunu ta’ theddida għall-ħajja tal-kelb tiegħek.

the main study was carried out in two phases in 151 dogs with mast cell tumours.
l-istudju prinċipali sar f’żewġ fażijiet fuq 151 kelb bit-tumuri tat-tip mast-cell.

canine mast cell tumour growth is frequently driven by an activating mutation in c-kit.
tumuri mast cell fil-klieb jikbru ta’ spiss minħabba mutazzjoni li tattiva is-c-kit.

there was no evidence of an anaphylactic response due to mast-cell degranulation in cynomolgus monkeys.
ma kienx hemm evidenza ta’ rispons anafilattiku permezz ta’ degranulazzjoni ta’ ċelluli tat-tip mast fix-xadini cynomolgus.

palladia is used to treat dogs with mast-cell tumours (a type of skin cancer).
palladia jintuża sabiex jittratta klieb b’tumuri tat-tip mast-cell (tip ta’ kanċer tal-ġilda).

en 1495:1997lifting platforms – mast climbing work platforms
en 1495:1997lifting platforms — mast climbing work platforms(il-pjattaformi ta’ l-irfigħ – pjattaformi taxxogħol xabbata ta’ larbli)

if gastrointestinal ulceration is suspected, whether or not due to palladia or to mast cell tumour degranulation, stop the administration of palladia and treat appropriately.
jekk hemm suspett ta’ ulċera gastro- intestinali, kemm jekk minħabba palladia jew minħabba mast cell tumour degranulation, waqqaf l- amministrazzjoni ta’ palladia u agħti t-trattament li jkun hemm bżonn.

masitinib treatment should only be used in dogs with non-resectable mast cell tumours and which express the mutated c-kit tyrosine kinase receptor.
it-trattament b’masitinib għandu jintuża biss fi klieb li jkollhom tumuri tal-mast cell li ma jkunux jistgħu jitneħħew u li jesprimu r-riċettur mibdul tal-c-kit tyrosine kinase.

some types of mast-cell tumour are linked to a mutation that causes excessive action of c-kit and stimulates the mast cells to divide uncontrollably.
xi tipi ta’ tumur taċ-ċelluli-mast huma marbutin ma’ tibdil ġenetiku li jikkaġuna azzjoni eċċessiva ta’ c-kit u jistimula liċ-ċelluli mast biex jinqasmu mingħajr kontroll.

treatment of non-resectable dog mast cell tumours (grade 2 or 3) with confirmed mutated c-kit tyrosine kinase receptor.
trattament ta’ tumuri tal-mast cell (grad 2 jew 3) fil-klieb u li ma jistgħux jitneħħew, b’riċettur mibdul ikkonfermat tal-c-kit tyrosine kinase.

data from in vitro studies suggest that it may act on human conjunctival mast cells to inhibit the release of pro-inflammatory mediators.
minn tagħrif ta 'studji in vitro jidher li jista ’ jaħdem fuq iċ- ċelluli mast tal- konġuntiva umana biex jinibixxi sustanzi pro- infjammatorji.

masivet is for the treatment of dogs with non-resectable mast cell tumours (grade 2 or 3) with a confirmed mutated c-kit tyrosine kinase receptor.
masivet jintuża għat-trattament ta’ klieb li jkollhom tumuri tal-mast cell (grad 2 jew 3) li ma jistgħux jitneħħew, b’riċettur mibdul ikkonfermat tal-c-kit tyrosine kinase.

iron or steel towers and lattice masts
torrijiet tal-ħadid jew l-azzar u arbli tal-kannizzati